Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CRSP vs FDMT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

FDMT Captures Overall Composite Edge (51.3 HOLD vs 44.7 HOLD), While CRSP Leads 3–2 on Growth & Valuation Pillars

FDMT Overall Winner 6-Pillar Tally: CRSP 3 – 2 FDMT (1 Tie) Matrix Metrics: CRSP 6 – 4 FDMT

As of Nov 16, 2026, 4D Molecular Therapeutics, Inc. (FDMT) captures the overall head-to-head institutional edge over CRISPR Therapeutics AG (CRSP) on higher Unified Composite conviction (51.3/100 HOLD vs. 44.7/100 HOLD) after splitting the core matrix 4–6 (led by Growth & Scale, Balance Sheet & Cash Flow), while CRSP wins 3–2 across the 6-pillar growth and valuation breakdown. CRSP trades at $40.61 (23.4x Forward P/E, -2058.6% operating margin) versus FDMT at $11.65 (N/M Forward P/E, -222.7% operating margin).

  • Growth vs. Quality Trade-Off: FDMT earns the overall head-to-head edge with a stronger Unified Composite Score (51.3/100 HOLD vs. CRSP 44.7/100 HOLD) and 1.89β · 90% Vol risk profile, whereas CRSP leads top-line expansion (+1325.1% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: CRSP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.6); meanwhile FDMT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CRSP vs FDMT
CRSP NASDAQ
CRISPR Therapeutics AG
Biological Products, (No Disgnostic Substances)
$40.61
-3.86% 1D
Market Cap $4.1B
TTM Revenue $25M
Forward P/E 23.4x
Beta / 30D Vol 1.85β · 60% Vol
Unified Composite Score
44.7 / 100 HOLD
Tech 25.0 Fund 52.0 Flow 68.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.6%), weak momentum, RSI 30
RSI-14: 29.6 · SMA20: $48.84 · SMA50: $51.79
FDMT NASDAQ Head-to-Head Winner
4D Molecular Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$11.65
-4.74% 1D
Market Cap $669.3M
TTM Revenue $96M
Forward P/E N/M
Beta / 30D Vol 1.89β · 90% Vol
Unified Composite Score
51.3 / 100 HOLD
Tech 51.0 Fund 47.0 Flow 66.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.3%), weak momentum, RSI 45
RSI-14: 44.9 · SMA20: $12.10 · SMA50: $13.07

6-Pillar Scorecard Institutional Category Breakdown (CRSP 3 – 2 FDMT)

Columns: Metric · CRSP · FDMT
1. Valuation Multiples CRSP
Forward P/E 23.4x N/M
Trailing P/E 23.4x N/M
PEG Ratio N/M N/M
EV / Revenue N/M 6.6x
2. Growth & Scale FDMT
Revenue Growth (YoY) +1325.1% +4505.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $25M $96M
Market Cap $4.1B $669.3M
3. Profitability & Quality CRSP
Gross Margin N/A N/A
Operating Margin -2058.6% -222.7%
Net Profit Margin 0.0% -208.6%
Return on Equity (ROE) -25.6% -56.7%
4. Balance Sheet & Cash Flow FDMT
Cash Generation (TTM) -$378M -$156M
Cash Flow Margin N/A N/A
Net Cash / Leverage $588M Net Debt (0.47x D/E) $31M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CRSP
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 97.8% (52nd %ile) 82.4% (10th %ile)
Put/Call OI Skew 0.65x (Call-Skewed) 5.16x (Put-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CRSP (6) vs FDMT (4)
Institutional Metric CRSP FDMT Criterion Row Edge
Market Capitalization
Scale
$4.1B $669.3M Larger Scale CRSP
Trailing P/E Ratio
Valuation
23.4x N/M Lower Multiple CRSP
Forward P/E Ratio
Valuation
23.4x N/M Lower Multiple CRSP
Revenue Growth (YoY)
Growth
+1325.1% +4505.6% Higher Growth FDMT
Operating Margin (TTM)
Profitability
-2058.6% -222.7% Higher Margin FDMT
Net Profit Margin
Profitability
0.0% -208.6% Higher Margin CRSP
Return on Equity (ROE)
Capital Efficiency
-25.6% -56.7% Higher ROE CRSP
52-Week Range Position
Momentum
1% ($40–$63) 47% ($7–$17) Stronger Trend FDMT
Beta / 30D Volatility
Risk Regime
1.85β · 60% Vol 1.89β · 90% Vol Lower Realized Risk CRSP
Unified Institutional Score
Composite Signal
44.7 / 100 (HOLD) 51.3 / 100 (HOLD) Higher Composite FDMT
Trailing 12M Revenue (USD)
Operating Scale
$25M $96M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 6.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$378M ($588M Net Debt (0.47x D/E)) -$156M ($31M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon FDMT +13.5 pp
CRSP: -17.54% · FDMT: -4.04%
3M Horizon FDMT +2.47 pp
CRSP: -23.33% · FDMT: -20.86%
6M Horizon FDMT +55.64 pp
CRSP: -16.37% · FDMT: +39.27%
1Y Horizon FDMT +33.87 pp
CRSP: -20.54% · FDMT: +13.33%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CRSP Revenue FDMT Revenue CRSP Op. Margin FDMT Op. Margin Margin Leader
FY2018 $0M N/A -5087.8% N/A CRSP
FY2019 $290M $10M 16.1% -729.4% CRSP
FY2020 $0M $10M -49295.5% -424.0% FDMT
FY2021 $910M $20M 40.8% -395.5% CRSP
FY2022 $0M $0M -56190.4% -3516.5% FDMT
FY2023 $370M $20M -60.0% -544.6% CRSP
FY2024 $40M $0M -1250.4% -507678.4% CRSP
FY2025 $0M $90M -18933.6% -187.2% FDMT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CRSP BREAKDOWN
58d in phase · OBV DISTRIBUTION
Current IV 97.8%
IV Percentile 52nd %ile
Put/Call OI Skew 0.65x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact CRSP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
FDMT BREAKDOWN
62d in phase · OBV NEUTRAL
Current IV 82.4%
IV Percentile 10th %ile
Put/Call OI Skew 5.16x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact FDMT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CRSP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $4.1B market capitalization and -2058.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
FDMT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $669.3M market capitalization and -222.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CRSP vs FDMT Key Questions & Quantitative Answers

As of Nov 16, 2026, 4D Molecular Therapeutics, Inc. (FDMT) captures the overall head-to-head institutional edge over CRISPR Therapeutics AG (CRSP) on higher Unified Composite conviction (51.3/100 HOLD vs. 44.7/100 HOLD) after splitting the core matrix 4–6 (led by Growth & Scale, Balance Sheet & Cash Flow), while CRSP wins 3–2 across the 6-pillar growth and valuation breakdown. CRSP trades at $40.61 (23.4x Forward P/E, -2058.6% operating margin) versus FDMT at $11.65 (N/M Forward P/E, -222.7% operating margin). Growth vs. Quality Trade-Off: FDMT earns the overall head-to-head edge with a stronger Unified Composite Score (51.3/100 HOLD vs. CRSP 44.7/100 HOLD) and 1.89β · 90% Vol risk profile, whereas CRSP leads top-line expansion (+1325.1% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: CRSP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.6); meanwhile FDMT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

FDMT leads the Growth & Scale pillar: CRSP posts +1325.1% YoY revenue growth and +0.0% YoY earnings growth on $25M TTM revenue (N/A gross margin, -2058.6% operating margin), compared with FDMT at +4505.6% YoY revenue growth and +0.0% YoY earnings growth on $96M TTM revenue (N/A gross margin, -222.7% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CRSP cumulative revenue shifted -86.2% while FDMT shifted +800.0%. In operating R&D and SG&A reinvestment, CRSP deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for FDMT.

CRSP screens cheaper on headline valuation multiples. CRSP trades at 23.4x Forward P/E, 23.4x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas FDMT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CRSP (-25.6% ROE) versus FDMT (-56.7% ROE) capital efficiency.

In options market volatility and institutional positioning, CRSP carries 97.8% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 0.65x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.85β · 60% Vol realized risk). By comparison, FDMT carries 82.4% implied volatility (10th %ile, Compressed (<25th %ile)), a 5.16x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.89β · 90% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.